Congress ticker disclosure profile

As of July 18 at 10:09 AM EDT

Public STOCK Act rows mentioning

IWF

A factual page for public Congressional disclosures that reference IWF. Veridion shows filed rows, disclosed amount ranges, dates, and source links. It does not imply motive or wrongdoing.

90d rows

0

Feed lifetime

61

Member filers

5

Disclosed ranges

$1.7M

Most active member desks

43 buys vs 18 sells

Thomas Macarthur46

Public filer · House · 3.0

Carlos Curbelo8

Republican · House · 26.0

David P. Joyce4

Republican · House · OH-14.0

Dan Sullivan2

Republican · Senate · AK

Thad Cochran1

Republican · House · US

Latest source-stamped receipts

Latest trade Jun 19, 2023

DateMemberActionAmountFiledReceipt
Jun 19, 2023David P. JoyceSellReceipt pending ingestionDate not disclosedReceipt pending ingestion
Jun 19, 2023David P. JoyceSell$15,001 to $50,000Aug 6, 2024Open card
Jul 17, 2019Dan SullivanSellReceipt pending ingestionAug 7, 2019Receipt pending ingestion
Dec 21, 2018Thomas MacarthurBuyReceipt pending ingestionDate not disclosedReceipt pending ingestion
Dec 21, 2018Thomas MacarthurBuy$1,001 to $15,000Jan 11, 2019Open card
Oct 2, 2018Dan SullivanSellReceipt pending ingestionNov 1, 2018Receipt pending ingestion
Oct 2, 2018Thomas MacarthurBuyReceipt pending ingestionDate not disclosedReceipt pending ingestion
Oct 2, 2018Thomas MacarthurBuy$1,001 to $15,000Dec 6, 2018Open card
Jul 10, 2018Thomas MacarthurBuyReceipt pending ingestionDate not disclosedReceipt pending ingestion
Jul 10, 2018Thomas MacarthurBuy$1,001 to $15,000Aug 3, 2018Open card
Apr 6, 2018Carlos CurbeloSellReceipt pending ingestionAug 2, 2018Receipt pending ingestion
Apr 6, 2018Carlos CurbeloSell$15,001 to $50,000Date not disclosedOpen card
Mar 28, 2018Thomas MacarthurBuy$1,001 to $15,000Date not disclosedOpen card
Feb 20, 2018Carlos CurbeloBuyReceipt pending ingestionMar 27, 2018Receipt pending ingestion
Feb 20, 2018Carlos CurbeloBuy$15,001 to $50,000Date not disclosedOpen card
Feb 6, 2018Carlos CurbeloSellReceipt pending ingestionMar 27, 2018Receipt pending ingestion
Feb 6, 2018Carlos CurbeloSell$15,001 to $50,000Date not disclosedOpen card
Jan 22, 2018Carlos CurbeloSell$1,001 to $15,000Feb 5, 2018Open card
Jan 12, 2018Thomas MacarthurSellReceipt pending ingestionDate not disclosedReceipt pending ingestion
Jan 12, 2018Thomas MacarthurSell$1,001 to $15,000Date not disclosedOpen card
Dec 28, 2017Thomas MacarthurBuy$1,001 to $15,000Date not disclosedOpen card
Oct 10, 2017Carlos CurbeloBuy$15,001 to $50,000Nov 3, 2017Open card
Sep 29, 2017Thomas MacarthurBuy$1,001 to $15,000Date not disclosedOpen card
Aug 17, 2017Thomas MacarthurBuyReceipt pending ingestionDate not disclosedReceipt pending ingestion
Aug 17, 2017Thomas MacarthurBuy$100,001 to $250,000Date not disclosedOpen card
Jul 12, 2017Thomas MacarthurBuy$1,001 to $15,000Date not disclosedOpen card
May 16, 2017Thomas MacarthurBuy$1,001 to $15,000Date not disclosedOpen card
May 16, 2017Thomas MacarthurBuy$15,001 to $50,000Date not disclosedOpen card
May 16, 2017Thomas MacarthurBuy$50,001 to $100,000Date not disclosedOpen card
Mar 30, 2017Thomas MacarthurBuyReceipt pending ingestionDate not disclosedReceipt pending ingestion
Mar 30, 2017Thomas MacarthurBuy$1,001 to $15,000Date not disclosedOpen card
Jan 30, 2017David P. JoyceBuy$100,001 to $250,000Date not disclosedOpen card
Jan 26, 2017David P. JoyceBuy$15,001 to $50,000Date not disclosedOpen card
Jan 9, 2017Thomas MacarthurSell$1,001 to $15,000Date not disclosedOpen card
Dec 29, 2016Thomas MacarthurBuy$1,001 to $15,000Date not disclosedOpen card
Sep 30, 2016Thomas MacarthurBuyReceipt pending ingestionDate not disclosedReceipt pending ingestion
Sep 30, 2016Thomas MacarthurBuy$1,001 to $15,000Date not disclosedOpen card
Jul 25, 2016Thomas MacarthurSellReceipt pending ingestionDate not disclosedReceipt pending ingestion
Jul 25, 2016Thomas MacarthurSell$100,001 to $250,000Aug 6, 2016Open card
Jul 12, 2016Thomas MacarthurBuy$1,001 to $15,000Aug 6, 2016Open card
Mar 30, 2016Thomas MacarthurBuyReceipt pending ingestionDate not disclosedReceipt pending ingestion
Mar 30, 2016Thomas MacarthurBuy$1,001 to $15,000Date not disclosedOpen card
Feb 1, 2016Thomas MacarthurSellReceipt pending ingestionDate not disclosedReceipt pending ingestion
Feb 1, 2016Thomas MacarthurSell$50,001 to $100,000Date not disclosedOpen card
Oct 1, 2015Thomas MacarthurBuyReceipt pending ingestionDate not disclosedReceipt pending ingestion
Oct 1, 2015Thomas MacarthurBuy$1,001 to $15,000Date not disclosedOpen card
Jul 9, 2015Thomas MacarthurBuyReceipt pending ingestionDate not disclosedReceipt pending ingestion
Jul 9, 2015Thomas MacarthurBuy$1,001 to $15,000Date not disclosedOpen card
Jun 2, 2015Thomas MacarthurBuyReceipt pending ingestionDate not disclosedReceipt pending ingestion
Jun 2, 2015Thomas MacarthurBuy$250,001 to $500,000Date not disclosedOpen card
Jun 1, 2015Thomas MacarthurBuyReceipt pending ingestionDate not disclosedReceipt pending ingestion
Jun 1, 2015Thomas MacarthurBuy$15,001 to $50,000Date not disclosedOpen card
Mar 18, 2015Thomas MacarthurSellReceipt pending ingestionDate not disclosedReceipt pending ingestion
Mar 18, 2015Thomas MacarthurSell$1,001 to $15,000Date not disclosedOpen card
Mar 3, 2015Thomas MacarthurBuyReceipt pending ingestionDate not disclosedReceipt pending ingestion
Mar 3, 2015Thomas MacarthurBuy$100,001 to $250,000Date not disclosedOpen card
Feb 23, 2015Thomas MacarthurBuyReceipt pending ingestionDate not disclosedReceipt pending ingestion
Feb 23, 2015Thomas MacarthurBuy$50,001 to $100,000Mar 11, 2015Open card
Jan 30, 2015Thomas MacarthurBuyReceipt pending ingestionDate not disclosedReceipt pending ingestion
Jan 30, 2015Thomas MacarthurBuy$1,001 to $15,000Mar 5, 2015Open card
Dec 9, 2014Thad CochranBuyReceipt pending ingestionJan 13, 2015Receipt pending ingestion

Source creed

This page is assembled from public STOCK Act disclosure records in the Veridion warehouse. 36 of 61 filed rows include disclosed amount ranges (59%). Rows without ranges stay labeled. Identification only; it does not imply motive or wrongdoing.

Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.